Long‐Term Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy ( <scp>HIPEC</scp> ) for Pseudomyxoma Peritonei: A 22‐Year Single Institution Experience
CRS and HIPEC is a safe and effective treatment for patients with PMP, demonstrating a 62% survival at 5 years. High-grade PMP histology and CEA ≥ 5 were independent predictors of worse OS. Our results demonstrate that comparable survival rates and recurrence free intervals to those reported by high-volume centres can be achieved, reinforcing the potential for successful outcomes in lower-volume settings while maintaining treatment quality and patient safety.
Authors
- Emma L. Bradshaw (ORCID: https://orcid.org/0000-0001-7894-8238)
- Susan L. Woods (ORCID: https://orcid.org/0000-0002-8955-2017)
- Markus Trochsler (ORCID: https://orcid.org/0000-0002-0650-9153)
- Nigel Da Silva (ORCID: https://orcid.org/0000-0003-3522-7419)
- Josephine A. Wright (ORCID: https://orcid.org/0000-0003-4588-8827)
- Peter J. Hewett (ORCID: https://orcid.org/0000-0002-8135-1317)
- Timothy Jay Price (ORCID: https://orcid.org/0000-0002-3922-2693)
- Harleen Kaur (ORCID: https://orcid.org/0009-0003-7411-2881)
- C Lauder
- Margarita‐Chrissi Litinas
Institutions
- Queen Elizabeth Hospital (AU)
- South Australian Health and Medical Research Institute (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- ANZ Journal of Surgery
- Published
- 2025-06-20
- DOI
- https://doi.org/10.1111/ans.70214
- Citations
- 1
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 2.01